Research On The Performance Of Fosun's Acquisition Of Alam Basing On DEA Model

This paper first expounds the background of the topic and the meaning of the topic,explains the research methods of this article,and points out the innovation and deficiencies of this paper.Next,the connotation and related theories related to M&A in this paper are expounded one by one,and the typical M&A performance evaluation methods are listed.The advantages and disadvantages of each method are analyzed,and the applicability is obtained.The M&A performance evaluation method applicable to this case is obtained.Then review and summarize the literature in the field of mergers and acquisitions at home and abroad,and prepare the theory for the following case analysis.Secondly,it introduces the acquisition of Fuxing's acquisition of Israel Alam.Firstly,it introduces the background of mergers and acquisitions,including the development history and current situation of China's pharmaceutical industry mergers and acquisitions,the overview of Fuxing and Alam,and the acquisition of Fuxing.course.The M&A process is further detailed,including M&A motives,mergers and acquisitions,and integration after mergers and acquisitions.Next,using the financial indicator analysis method and the DEA model analysis method,based on the financial indicator data before and after the acquisition,the performance of Fuxing's acquisition of Fuxing before and after Israel's Alam was compared and analyzed,and the company's performance after the acquisition was significantly stronger than that.Before the acquisition,the acquisition was successful for Fuxing.Finally,based on the acquisition of Israel Alam by Fuxing Pharma,the experience of the merger was summarized.First of all,under the background of “Belt and Road”,it provides feasible suggestions for the rough selection of M&A work in China's pharmaceutical industry.Secondly,it analyzes the opportunities and challenges that Chinese pharmaceutical industry enterprises bring to overseas M&A.Next,the paper summarizes the risk factors faced by Chinese pharmaceutical companies in implementing overseas mergers and acquisitions,and puts forward practical suggestions for each risk factor.